Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)

This study is currently recruiting participants.
Verified May 2012 by University of Colorado, Boulder
Forest Laboratories
Information provided by (Responsible Party):
Christopher DeSouza, University of Colorado, Boulder Identifier:
First received: March 5, 2012
Last updated: May 8, 2012
Last verified: May 2012

The investigators hypothesize that nebivolol will improve endothelial t-PA release in adult humans with elevated blood pressure to a greater extent than either metoprolol or placebo. The investigators further hypothesize that the improvement in the capacity of the vascular endothelium to release t-PA with nebivolol is mediated, in part, by the compound's antioxidant properties.

Condition Intervention Phase
Drug: Nebivolol
Drug: Metoprolol
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Official Title: Nebivolol and Endothelial Regulation of Fibrinolysis

Resource links provided by NLM:

Further study details as provided by University of Colorado, Boulder:

Primary Outcome Measures:
  • Changes from baseline in endothelial t-PA release [ Time Frame: t-PA release will be measured at week 3 (before the 12 week drug or placebo intervention) and at week 15 (after the 12 week drug or placebo intervention). ] [ Designated as safety issue: No ]
    t-PA release is measured in response the bradykinin, sodium nitroprusside, vitamin C and bradykinin+vitamin C

Estimated Enrollment: 54
Study Start Date: February 2012
Estimated Study Completion Date: February 2014
Estimated Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Nebivolol Drug: Nebivolol
5 mg tablet to be taken by mouth once per day for 12 weeks
Other Name: Bystolic
Active Comparator: Metoprolol Drug: Metoprolol
100 mg tablet to be taken by mouth once per day for 12 weeks
Other Name: Toprol-XL
Placebo Comparator: Placebo Drug: Placebo
Gelatin capsule to be taken by mouth once per day for 12 weeks


Ages Eligible for Study:   45 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects will be men and women of all races and ethnic backgrounds aged 45-65 years.
  • Subjects will be prehypertensive/hypertensive defined as resting systolic blood pressure >125 mmHg and <160 mmHg and/or diastolic >80 mmHg and <100 mmHg.
  • All of the women in the study will be postmenopausal and not receiving hormone replacement therapy (HRT) currently or in the preceding 3-year period.
  • Candidates will be sedentary as determined from the Stanford Physical Activity Questionnaire (<35 kcal/wk) and will not have engaged in any program of regular physical activity for at least 1 year prior to the study.

Exclusion Criteria:

  • Candidates who smoke (currently or in the past 7 years), report more than low-risk alcohol consumption as defined as no more than 14 standard drinks/wk and no more than 4 standard drinks/day for men and 7 standard drinks/wk and 3 standard drinks/day for women (a standard drink is defined as 12 ounces of beer, 5 ounces of wine, 1½ ounces of 80-proof distilled spirits).
  • Potential candidates who are taking cardiovascular-acting (i.e. statins, blood pressure medication and aspirin) medications will not be eligible.
  • Fasting plasma glucose >126 mg/dL.
  • Potential candidates with a resting heart rate of < 50 beats/minute will be excluded.
  • Use of hormone replacement therapy.
  • In hypertensive subjects, a seated systolic blood pressure >160 mmHg or a seated diastolic blood pressure >100 mmHg will be excluded.
  Contacts and Locations
Please refer to this study by its identifier: NCT01595516

Contact: Jared Greiner, M.S. 303-735-4955

United States, Colorado
UC-Boulder Clinical and Translational Research Center Recruiting
Boulder, Colorado, United States, 80309
Contact    303-735-3056      
Principal Investigator: Christopher DeSouza, Ph.D.         
Sponsors and Collaborators
University of Colorado, Boulder
Forest Laboratories
Principal Investigator: Christopher DeSouza, Ph.D. University of Colorado at Boulder
  More Information

No publications provided

Responsible Party: Christopher DeSouza, Professor, University of Colorado, Boulder Identifier: NCT01595516     History of Changes
Other Study ID Numbers: BYS-MD-72
Study First Received: March 5, 2012
Last Updated: May 8, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Metoprolol succinate
Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Antihypertensive Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents processed this record on April 17, 2014